Der blev observeret en stigning til ca. det dobbelte i sitagliptins plasma AUC hos patienter med moderat nyreinsufficiens, og en stigning til ca. det firdobbelte blev observeret hos patienter med svær nyreinsufficiens og hos patienter med ESRD i hæmodialyse sammenlignet med normale raske kontrolpersoner.
An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal insufficiency, and an approximately 4-fold increase was observed in patients with severe renal insufficiency and in patients with ESRD on haemodialysis, as compared to normal healthy control subjects.